Free Trial

Vericel (VCEL) Competitors

Vericel logo
$34.27 +0.68 (+2.02%)
As of 03:16 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

VCEL vs. ABVX, CRSP, NUVL, AXSM, LEGN, TGTX, PCVX, MTSR, KRYS, and PTCT

Should you be buying Vericel stock or one of its competitors? The main competitors of Vericel include Abivax (ABVX), CRISPR Therapeutics (CRSP), Nuvalent (NUVL), Axsome Therapeutics (AXSM), Legend Biotech (LEGN), TG Therapeutics (TGTX), Vaxcyte (PCVX), Metsera (MTSR), Krystal Biotech (KRYS), and PTC Therapeutics (PTCT). These companies are all part of the "pharmaceutical products" industry.

Vericel vs. Its Competitors

Vericel (NASDAQ:VCEL) and Abivax (NASDAQ:ABVX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

Vericel has higher revenue and earnings than Abivax.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vericel$237.22M7.38$10.36M$0.12289.21
AbivaxN/AN/A-$190.71MN/AN/A

Vericel has a net margin of 2.85% compared to Abivax's net margin of 0.00%. Vericel's return on equity of 2.47% beat Abivax's return on equity.

Company Net Margins Return on Equity Return on Assets
Vericel2.85% 2.47% 1.69%
Abivax N/A N/A N/A

47.9% of Abivax shares are owned by institutional investors. 5.2% of Vericel shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Vericel had 2 more articles in the media than Abivax. MarketBeat recorded 16 mentions for Vericel and 14 mentions for Abivax. Abivax's average media sentiment score of 0.53 beat Vericel's score of 0.12 indicating that Abivax is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Vericel
3 Very Positive mention(s)
4 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Abivax
3 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

Vericel has a beta of 1.39, indicating that its share price is 39% more volatile than the S&P 500. Comparatively, Abivax has a beta of 0.39, indicating that its share price is 61% less volatile than the S&P 500.

Vericel presently has a consensus price target of $58.40, suggesting a potential upside of 68.28%. Abivax has a consensus price target of $114.25, suggesting a potential upside of 23.13%. Given Vericel's higher possible upside, equities analysts clearly believe Vericel is more favorable than Abivax.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vericel
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.71
Abivax
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.91

Summary

Vericel beats Abivax on 9 of the 13 factors compared between the two stocks.

Get Vericel News Delivered to You Automatically

Sign up to receive the latest news and ratings for VCEL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VCEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VCEL vs. The Competition

MetricVericelMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.77B$3.39B$6.15B$10.47B
Dividend YieldN/A2.30%5.73%4.78%
P/E Ratio292.0722.9785.0727.24
Price / Sales7.38435.83573.51178.32
Price / Cash110.8546.1137.3961.86
Price / Book5.8610.5212.426.70
Net Income$10.36M-$52.47M$3.32B$276.79M
7 Day Performance5.90%-0.06%0.28%-0.86%
1 Month Performance4.44%15.60%10.06%6.26%
1 Year Performance-15.91%15.29%72.23%37.64%

Vericel Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VCEL
Vericel
3.3101 of 5 stars
$34.27
+2.0%
$58.40
+70.4%
-19.9%$1.73B$237.22M285.27300Trending News
Analyst Upgrade
Analyst Revision
ABVX
Abivax
3.0125 of 5 stars
$86.67
+3.3%
$103.29
+19.2%
+908.5%$6.34BN/A0.0061Analyst Forecast
High Trading Volume
CRSP
CRISPR Therapeutics
1.6482 of 5 stars
$70.19
+3.6%
$71.50
+1.9%
+49.5%$6.16B$37.31M-12.93460News Coverage
Analyst Forecast
Insider Trade
NUVL
Nuvalent
2.9312 of 5 stars
$83.85
-0.4%
$118.89
+41.8%
-12.5%$6.07BN/A-17.1140Trending News
Analyst Forecast
Insider Trade
AXSM
Axsome Therapeutics
4.6942 of 5 stars
$119.94
-0.3%
$177.93
+48.4%
+49.9%$6.00B$385.69M-23.66380Analyst Revision
LEGN
Legend Biotech
2.7978 of 5 stars
$31.44
-1.9%
$74.22
+136.1%
-24.9%$5.92B$627.24M-35.732,609News Coverage
Gap Up
TGTX
TG Therapeutics
4.403 of 5 stars
$36.76
+0.1%
$49.00
+33.3%
+42.7%$5.82B$329M99.35290Positive News
PCVX
Vaxcyte
2.3021 of 5 stars
$41.21
-3.4%
$106.25
+157.8%
-62.0%$5.54BN/A-10.03160News Coverage
Analyst Forecast
MTSR
Metsera
N/A$52.50
+1.2%
$55.75
+6.2%
N/A$5.45BN/A0.0081
KRYS
Krystal Biotech
4.3725 of 5 stars
$180.57
-1.5%
$209.00
+15.7%
+8.1%$5.31B$290.52M36.70210News Coverage
Analyst Revision
PTCT
PTC Therapeutics
3.3822 of 5 stars
$64.80
-0.9%
$69.00
+6.5%
+82.4%$5.19B$1.76B9.301,410Analyst Revision

Related Companies and Tools


This page (NASDAQ:VCEL) was last updated on 10/16/2025 by MarketBeat.com Staff
From Our Partners